Addison's Disease Treatment Market by Drug Class (Glucocorticoid, Mineralocorticoid), Diagnosis (Imaging Testing, Laboratory Testing), Treatments, Distribution Channel, Route of Administration - Global Forecast 2024-2030
The Addison's Disease Treatment Market size was estimated at USD 1.41 billion in 2023 and expected to reach USD 1.54 billion in 2024, at a CAGR 10.72% to reach USD 2.88 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Addison's Disease Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Addison's Disease Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Addison's Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Actiza Pharmaceutical Private Limited, Akorn Operating Company LLC, Amgen Inc., Amneal Pharmaceuticals, Inc., Bay Biosciences LLC, Bayer AG, Bio-Techne Corporation, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, BTL Biotechno Labs Pvt Ltd., Cardinal Health, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, LUMITOS AG, Lupin Limited, Merck KGaA, Neurocrine Biosciences, Inc., Novartis AG, Pfizer Inc., Recipharm AB, Sandoz International GmbH, and Takeda Pharmaceutical Company Limited.
Market Segmentation & Coverage
This research report categorizes the Addison's Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
Drug Class
Glucocorticoid
Dexamethasone
Fludrocortisone
Imaging Testing
Corticosteroid Injections
E-Commerce
Oral
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Addison's Disease Treatment Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Addison's Disease Treatment Market?
- What are the technology trends and regulatory frameworks in the Addison's Disease Treatment Market?
- What is the market share of the leading vendors in the Addison's Disease Treatment Market?
- Which modes and strategic moves are suitable for entering the Addison's Disease Treatment Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Addison's Disease Treatment Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising incidences of Addison's disease globally
- 5.1.1.2. Growing awareness regarding adrenal insufficiency
- 5.1.1.3. Inception of robust healthcare infrastructure and favorable reimbursement policies
- 5.1.2. Restraints
- 5.1.2.1. High costs associated with the Addison treatment medications
- 5.1.3. Opportunities
- 5.1.3.1. Growing demand for new generation technologically integrated advanced therapeutic drugs
- 5.1.3.2. Increasing R&D activities and rising focus of the companies in developing treatments for Addison's disease
- 5.1.4. Challenges
- 5.1.4.1. Lack of awareness among people regarding Addison's disease
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Addison's Disease Treatment Market, by Drug Class
- 6.1. Introduction
- 6.2. Glucocorticoid
- 6.3.1. Dexamethasone
- 6.3.2. Hydrocortisone
- 6.3.3. Prednisone
- 6.3. Mineralocorticoid
- 6.4.1. Fludrocortisone
- 7. Addison's Disease Treatment Market, by Diagnosis
- 7.1. Introduction
- 7.2. Imaging Testing
- 7.3. Laboratory Testing
- 8. Addison's Disease Treatment Market, by Treatments
- 8.1. Introduction
- 8.2. Corticosteroid Injections
- 8.3. Naturopathic Solutions
- 8.4. Oral Corticosteroids
- 9. Addison's Disease Treatment Market, by Distribution Channel
- 9.1. Introduction
- 9.2. E-Commerce
- 9.3. Hospital Pharmacy
- 9.4. Retail Pharmacy
- 10. Addison's Disease Treatment Market, by Route of Administration
- 10.1. Introduction
- 10.2. Oral
- 10.3. Parental
- 11. Americas Addison's Disease Treatment Market
- 11.1. Introduction
- 11.2. Argentina
- 11.3. Brazil
- 11.4. Canada
- 11.5. Mexico
- 11.6. United States
- 12. Asia-Pacific Addison's Disease Treatment Market
- 12.1. Introduction
- 12.2. Australia
- 12.3. China
- 12.4. India
- 12.5. Indonesia
- 12.6. Japan
- 12.7. Malaysia
- 12.8. Philippines
- 12.9. Singapore
- 12.10. South Korea
- 12.11. Taiwan
- 12.12. Thailand
- 12.13. Vietnam
- 13. Europe, Middle East & Africa Addison's Disease Treatment Market
- 13.1. Introduction
- 13.2. Denmark
- 13.3. Egypt
- 13.4. Finland
- 13.5. France
- 13.6. Germany
- 13.7. Israel
- 13.8. Italy
- 13.9. Netherlands
- 13.10. Nigeria
- 13.11. Norway
- 13.12. Poland
- 13.13. Qatar
- 13.14. Russia
- 13.15. Saudi Arabia
- 13.16. South Africa
- 13.17. Spain
- 13.18. Sweden
- 13.19. Switzerland
- 13.20. Turkey
- 13.21. United Arab Emirates
- 13.22. United Kingdom
- 14. Competitive Landscape
- 14.1. FPNV Positioning Matrix
- 14.2. Market Share Analysis, By Key Player
- 14.3. Competitive Scenario Analysis, By Key Player
- 15. Competitive Portfolio
- 15.1. Key Company Profiles
- 15.1.1. Abbott Laboratories
- 15.1.2. Actiza Pharmaceutical Private Limited
- 15.1.3. Akorn Operating Company LLC
- 15.1.4. Amgen Inc.
- 15.1.5. Amneal Pharmaceuticals, Inc.
- 15.1.6. Bay Biosciences LLC
- 15.1.7. Bayer AG
- 15.1.8. Bio-Techne Corporation
- 15.1.9. Biogen Inc.
- 15.1.10. Boehringer Ingelheim International GmbH
- 15.1.11. Bristol-Myers Squibb Company
- 15.1.12. BTL Biotechno Labs Pvt Ltd.
- 15.1.13. Cardinal Health, Inc.
- 15.1.14. Eli Lilly and Company
- 15.1.15. GlaxoSmithKline PLC
- 15.1.16. Hikma Pharmaceuticals PLC
- 15.1.17. LUMITOS AG
- 15.1.18. Lupin Limited
- 15.1.19. Merck KGaA
- 15.1.20. Neurocrine Biosciences, Inc.
- 15.1.21. Novartis AG
- 15.1.22. Pfizer Inc.
- 15.1.23. Recipharm AB
- 15.1.24. Sandoz International GmbH
- 15.1.25. Takeda Pharmaceutical Company Limited
- 15.2. Key Product Portfolio
- 16. Appendix
- 16.1. Discussion Guide
- 16.2. License & Pricing
- FIGURE 1. ADDISON'S DISEASE TREATMENT MARKET RESEARCH PROCESS
- FIGURE 2. ADDISON'S DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
- FIGURE 3. ADDISON'S DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ADDISON'S DISEASE TREATMENT MARKET DYNAMICS
- FIGURE 7. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 8. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
- FIGURE 10. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2023 VS 2030 (%)
- FIGURE 12. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 14. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 16. ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 20. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 25. ADDISON'S DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 26. ADDISON'S DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook